Tisotumab Vedotin Yields Promising Preliminary Activity in SCCHNMarch 2nd 2022
Patients with squamous cell carcinoma of the head and neck who had progressive disease following treatment with platinum-based chemotherapy and a checkpoint inhibitor experienced promising safety and preliminary efficacy following treatment with tisotumab vedotin.
Circulating TTMV HPV Tumor DNA May Detect Recurrence of HPV-Driven Oropharyngeal CancersFebruary 25th 2022
Research presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium highlighted the potential to detect oropharyngeal cancer recurrence using circulating tumor tissue modified viral–human papillomavirus DNA.
Radiotherapy De-Escalation Improves Toxicity in p16+ Oropharyngeal Squamous Cell CarcinomaFebruary 25th 2022
A presentation from the 2022 ASTRO Multidisciplinary Head and Neck Cancers Symposium showed a de-escalated radiotherapy dose to 54 Gy vs 70 Gy led to better measures of toxicity in those with p16+ oropharyngeal squamous cell carcinoma.
DART Meets Noninferiority PFS Benchmark in HPV-Related OPSCCFebruary 25th 2022
In a pre-planned pooled analysis of data from the MC1273 and MC1675 trials presented at the 2022 ASTRO Multidisciplinary Head and Neck Cancers Symposium, de-escalated adjuvant radiation therapy met criteria for efficacy in human papillomavirus–related oropharyngeal squamous cell carcinoma.